AMENDMENT AGREEMENTAmendment Agreement • March 15th, 2018 • Alliqua BioMedical, Inc. • Surgical & medical instruments & apparatus • New York
This AMENDMENT AGREEMENT, dated as of March 13, 2018 (this “Agreement”), is made by and among ALLIQUA BIOMEDICAL, INC., a Delaware corporation (the “Borrower”), AQUAMED TECHNOLOGIES, INC., a Delaware corporation (the “Guarantor”; each of the Borrower and the Guarantor also is referred to herein individually as an “Obligor” and collectively as the “Obligors”), and PERCEPTIVE CREDIT HOLDINGS, LP, a Delaware limited partnership (the “Lender”). Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided in the Credit Agreement (defined below).
BRIDGE LOAN NOTEAlliqua BioMedical, Inc. • March 15th, 2018 • Surgical & medical instruments & apparatus
FOR VALUE RECEIVED, ALLIQUA BIOMEDICAL, INC., a Delaware corporation (the “Borrower”), promises to pay to PERCEPTIVE CREDIT HOLDINGS, LP (together with any of its successors, transferees and assignees, the “Lender”) on the Maturity Date (as such date may be accelerated pursuant to the Credit Agreement, defined below) the principal sum of TWO MILLION DOLLARS ($2,000,000.00) or, if less, the aggregate unpaid principal amount of the Bridge Loan shown on the grid attached to this Bridge Loan Note (this “Note”) as Schedule A (and any continuation thereof) made by the Lender pursuant to the Credit Agreement and Guaranty, dated as of May 29, 2015 (as amended or otherwise modified from time to time, the “Credit Agreement”), by and among the Borrower, each Guarantor party thereto and the Lender. Unless otherwise defined, capitalized terms used herein have the meanings provided in the Credit Agreement.
GENERAL RELEASE AND SEVERANCE AGREEMENTGeneral Release and Severance Agreement • March 15th, 2018 • Alliqua BioMedical, Inc. • Surgical & medical instruments & apparatus • Delaware
This General Release and Severance Agreement (the “Agreement”), dated as of March 15, 2018, is made and entered into by and between Brian Posner and Alliqua Biomedical, Inc. (“Alliqua”).
